StreetInsider.com News Articles

Vaxart receives European patent for oral norovirus vaccine technology

Wed, 26 Aug 2026 16:08:16 -0400

Vaxart, Inc. (OTCQX: VXRT) announced that the European Patent Office granted the company European Patent No. 3791859, published Aug. 26, 2026, covering key aspects of its oral recombinant norovirus vaccine candidate.

The patent provides intellectual property protection through at least 2036 across 13 European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom. Additional countries where the patent will be validated include Austria, Belgium, Denmark, Ireland, Netherlands, Norway, Sweden, and Switzerland.

The patent covers elements of Vaxart's pill-based vaccine delivery technology, which the company describes as room-temperature stable and needle-free.

"Securing this patent expands our global intellectual property portfolio and secures additional

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Wed, 26 Aug 2026 16:07:00 -0400

KEY HIGHLIGHTS:
• European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart's oral recombinant norovirus vaccine candidate.
• Extended Intellectual Property Protection secured through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom.
• Proprietary Delivery Platform Validation: Protects key aspects of Vaxart's room-temperature stable, needle-free pill technology for the use of against norovirus.

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Wed, 26 Aug 2026 16:07:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Wed, 26 Aug 2026 16:07:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Wed, 26 Aug 2026 16:07:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Wed, 26 Aug 2026 16:07:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Wed, 26 Aug 2026 16:07:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Wed, 26 Aug 2026 16:07:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Wed, 26 Aug 2026 16:07:00 -0400

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range

Form 8-K Vaxart, Inc. For: Aug 21

Tue, 25 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260825/26974878.html

Form 8-K Vaxart, Inc. For: Aug 21

Tue, 25 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260825/26974878.html

Vaxart (VXRT) Misses Q2 EPS by 3c

Thu, 06 Aug 2026 17:03:46 -0400

Vaxart (NASDAQ: VXRT) reported Q2 EPS of ($0.06), $0.03 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $27.19 million versus the consensus estimate of $50.5 million.

For earnings history and earnings-related data on Vaxart (VXRT) click here.

Form 10-Q Vaxart, Inc. For: Jun 30

Thu, 06 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260806/26884571.html

Form 10-Q Vaxart, Inc. For: Jun 30

Thu, 06 Aug 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260806/26884571.html

Form 8-K Vaxart, Inc. For: Aug 06

Thu, 06 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260806/26884362.html

Form 8-K Vaxart, Inc. For: Aug 06

Thu, 06 Aug 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260806/26884362.html

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

Thu, 06 Aug 2026 16:05:00 -0400

Reported topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial; Topline data from 400-person sentinel safety cohort and approximately 5,000 participants in main cohort anticipated in first half of 2027